Seeger Weiss Welcomes Former Assistant U.S. Attorney Michael Castiglione as Firm Continues to Build Deep Bench of Talented Attorneys

Seeger Weiss is proud to announce that Michael Castiglione has joined the firm as Counsel, bringing nearly two decades of experience in in high-stakes litigation, government investigations, and complex civil matters.

April 1, 2026

Michael Castiglione

Seeger Weiss is proud to announce that Michael Castiglione has joined the firm as Counsel, bringing nearly two decades of experience in in high-stakes litigation, government investigations, and complex civil matters.

Castiglione comes to Seeger Weiss following more than a decade as an Assistant United States Attorney (AUSA) in the Eastern District of New York, where he served in both the Civil and Criminal divisions. In the Civil Division, he served as lead counsel in United States v. UBS Securities, which resulted in a $1.435 billion settlement, the DOJ’s largest civil fraud recovery in 2023. Most recently, in the Criminal Division, he led grand jury investigations and prosecuted cases involving financial fraud, money laundering, tax offenses, and violent crime. He earned both the Attorney General’s Award for Fraud Prevention and the EOUSA Director’s Award for Superior Performance by a Litigative Team. Before entering public service, Castiglione practiced at Simpson Thacher & Bartlett LLP where he managed government investigations and litigated a broad range of state and federal matters, including securities, antitrust, and insurance coverage cases.

“Michael brings exactly the kind of depth, judgment, and courtroom experience that defines Seeger Weiss,” said Founding Partner Christopher A. Seeger. “His leadership in some of the most sophisticated fraud, forfeiture, and financial investigations in the country makes him a powerful addition to our team as we continue to expand the breadth of our complex, high-impact litigation.”

Castiglione’s arrival follows that of Daniel Marcet, also a former senior federal prosecutor, who joined the firm as Counsel in late December. The additions of Castiglione and Marcet reflect a focused effort by Seeger Weiss to add top-tier talent to plaintiff-side litigation.

Castiglione holds a J.D. from the University of Virginia School of Law, where he served on the editorial board of the Virginia Law Review, and a B.A. from Columbia College.

Learn more about Michael: https://www.seegerweiss.com/team/michael-castiglione/.

Prior results do not guarantee or predict a similar outcome in any future matter.

Related News

March 30, 2026
Ten Seeger Weiss Attorneys Named To The 2026 Lawdragon 500 Leading Plaintiff Financial Lawyers Guide

Seeger Weiss is proud to announce that ten Seeger Weiss attorneys have been selected for inclusion in The 2026 Lawdragon 500 Leading Plaintiff Financial Lawyers guide. Congratulations to Christopher Seeger, Stephen Weiss, Parvin K. Aminolroaya, Ben Barnett, David R. Buchanan, Steven Daroci, Shauna Itri, Jeremy Kasha, Jennifer Scullion, and Caleb Seeley on this well-deserved recognition. […]

Read More
March 26, 2026
Jury Finds Meta and YouTube Liable in Landmark California Social Media Addiction Trial

A California jury has found Meta and YouTube negligent in designing platforms that harmed a young user, ordering Meta to pay $4.2 million and YouTube to pay $1.8 million in combined compensatory and punitive damages, in what is being called a landmark verdict in social media addiction litigation. Seeger Weiss Founding Partner Christopher Seeger serves […]

Read More
March 12, 2026
Seeger Weiss Partner Parvin Aminolroaya and Counsel Max Kelly Appointed to Leadership Roles in GLP-1 NAION Products Liability Litigation

Seeger Weiss is proud to announce that Partner Parvin Aminolroaya has been appointed Co-Lead Counsel for Plaintiffs in the In Re: GLP-1 RAS Non-arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation and Counsel Max Kelly has been appointed to the Plaintiffs’ Executive Committee. The litigation involves claims that GLP-1 receptor agonist drugs including Ozempic, Wegovy, […]

Read More